Fennec Pharmaceuticals Inc. Common Stock FENC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:54:43.188Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:00.639867247Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T13:54:42.845161+00:00
Fennec Pharmaceuticals Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.64 | 695.7% | 51.4% | |||
| 25Δ | 8.52 | 597.9% | 43.1% | |||
| 30Δ | 9.40 | 500.2% | 34.7% | |||
| 35Δ | 10.13 | 421.9% | 27.9% | |||
| 40Δ | 10.52 | 384.2% | 24.3% | |||
| 45Δ | 10.91 | 346.6% | 20.7% | |||
| 50Δ | 17.23 | 617.8% | 86.5% | 11.30 | 308.9% | 17.0% |
| 55Δ | 13.22 | 495.9% | 48.6% | 11.70 | 271.2% | 13.4% |
| 60Δ | 11.37 | 411.1% | 31.1% | 12.09 | 233.5% | 9.8% |
| 65Δ | 9.95 | 339.0% | 18.0% | 12.48 | 195.9% | 6.1% |
| 70Δ | 9.12 | 340.9% | 15.2% | |||
| 75Δ | 8.29 | 342.8% | 12.5% | |||
| 80Δ | 7.45 | 344.7% | 9.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.64
- IV
- 695.7%
- B/E move
- 51.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.52
- IV
- 597.9%
- B/E move
- 43.1%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.40
- IV
- 500.2%
- B/E move
- 34.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.13
- IV
- 421.9%
- B/E move
- 27.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.52
- IV
- 384.2%
- B/E move
- 24.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.91
- IV
- 346.6%
- B/E move
- 20.7%
50Δ
- Pseudo strike
- 17.23
- IV
- 617.8%
- B/E move
- 86.5%
- Pseudo strike
- 11.30
- IV
- 308.9%
- B/E move
- 17.0%
55Δ
- Pseudo strike
- 13.22
- IV
- 495.9%
- B/E move
- 48.6%
- Pseudo strike
- 11.70
- IV
- 271.2%
- B/E move
- 13.4%
60Δ
- Pseudo strike
- 11.37
- IV
- 411.1%
- B/E move
- 31.1%
- Pseudo strike
- 12.09
- IV
- 233.5%
- B/E move
- 9.8%
65Δ
- Pseudo strike
- 9.95
- IV
- 339.0%
- B/E move
- 18.0%
- Pseudo strike
- 12.48
- IV
- 195.9%
- B/E move
- 6.1%
70Δ
- Pseudo strike
- 9.12
- IV
- 340.9%
- B/E move
- 15.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 8.29
- IV
- 342.8%
- B/E move
- 12.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 7.45
- IV
- 344.7%
- B/E move
- 9.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 204.64% | |
| 258.65% | |
| 299.38% | |
| 155.13% | |
| 165.58% | |
| 139.89% | |
| 166.84% | |
| 150.97% | |
| 150.24% | |
| 173.17% | |
| 172.76% | |
| 172.16% | |
| 159.76% | |
| 150.09% | |
| 221.28% | |
| 229.10% | |
| 275.43% | |
| 280.33% | |
| 236.45% | |
| 153.98% | |
| 165.69% | |
| 164.32% | |
| 164.31% | |
| 170.17% | |
| 168.91% | |
| 170.35% | |
| 176.58% | |
| 181.57% | |
| 190.89% | |
| 188.58% | |
| 202.83% | |
| 212.79% | |
| 218.83% | |
| 221.67% | |
| 226.62% | |
| 266.90% | |
| 175.16% | |
| 173.86% | |
| 170.74% | |
| 173.04% | |
| 176.76% | |
| 183.45% | |
| 189.87% | |
| 181.02% | |
| 175.76% | |
| 175.38% | |
| 197.14% |
Biotechnology
FLNA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach,…
More →FTRE
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
More →FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas…
More →GALT
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The…
More →GANX
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is…
More →GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →